|
6331 |
Wissenschaftliche Basis unserer Therapien nicht diskreditieren!
Enthalten in Der Neurologe & Psychiater Bd. 18, 7.3.2017, Nr. 3, date:3.2017: 3
|
|
|
|
6332 |
Workplace violence in a tertiary care Israeli hospital - a systematic analysis of the types of violence, the perpetrators and hospital departments
Enthalten in Israel Journal of Health Policy Research Bd. 6, 23.8.2017, Nr. 1, date:12.2017: 1-11
|
|
|
|
6333 |
Worlds apart? A scoping review addressing different stakeholder perspectives on barriers to family involvement in the care for persons with severe mental illness
Enthalten in BMC health services research Bd. 17, 15.5.2017, Nr. 1, date:12.2017: 1-10
|
|
|
|
6334 |
Worldwide research productivity in the field of psychiatry
Enthalten in International journal of mental health systems Bd. 11, 14.2.2017, Nr. 1, date:12.2017: 1-6
|
|
|
|
6335 |
Wozu Bindung(en) mitdenken?
Enthalten in Psychopraxis. Neuropraxis Bd. 21, 6.12.2017, Nr. 1, date:2.2018: 32-36
|
|
|
|
6336 |
Youth experiences of transition from child mental health services to adult mental health services: a qualitative thematic synthesis
Enthalten in BMC psychiatry Bd. 17, 28.11.2017, Nr. 1, date:12.2017: 1-11
|
|
|
|
6337 |
Ziele, Werte und Sinn
Enthalten in Psychotherapeut Bd. 62, 11.9.2017, Nr. 5, date:9.2017: 469-482
|
|
|
|
6338 |
Zulassungsempfehlung für Ocrelizumab
Enthalten in Neurotransmitter Bd. 29, 13.1.2018, Nr. 1, date:1.2018: 61
|
|
|
|
6339 |
Zulassungsempfehlung für Ocrelizumab
Enthalten in Info Neurologie & Psychiatrie Bd. 20, 22.1.2018, Nr. 1, date:1.2018: 51
|
|
|
|
6340 |
Zulassungsempfehlung für Ocrelizumab
Enthalten in Neurotransmitter Bd. 29, 6.2.2018, Nr. 2, date:2.2018: 49
|
|
Administration
